{"id":17712,"date":"2026-09-11T10:56:05","date_gmt":"2026-09-11T10:56:05","guid":{"rendered":"https:\/\/veilles-affaires-sociales.fr\/?p=17712"},"modified":"2026-09-11T10:56:05","modified_gmt":"2026-09-11T10:56:05","slug":"points-forts-de-la-reunion-du-comite-des-medicaments-veterinaires-cvmp-8-10-septembre-2026-titre-traduit-en-francais-par-lia","status":"publish","type":"post","link":"https:\/\/veilles-affaires-sociales.fr\/?p=17712","title":{"rendered":"Points forts de la r\u00e9union du Comit\u00e9 des m\u00e9dicaments v\u00e9t\u00e9rinaires (CVMP) 8-10 septembre 2026\u00a0(titre traduit en fran\u00e7ais par l&rsquo;IA)"},"content":{"rendered":"<p>Le Comit\u00e9 des m\u00e9dicaments \u00e0 usage v\u00e9t\u00e9rinaire (CVMP) de l\u2019Agence europ\u00e9enne des m\u00e9dicaments a adopt\u00e9 plusieurs avis positifs portant sur des autorisations de mise sur le march\u00e9 (AMM) et des variations d\u2019AMM de m\u00e9dicaments v\u00e9t\u00e9rinaires, principalement destin\u00e9s aux porcs, volailles, chevaux, chats et chiens.<\/p>\n<p>Une AMM a \u00e9t\u00e9 recommand\u00e9e pour Cirbloc, indiqu\u00e9 pour l\u2019immunisation active des porcs \u00e0 partir de trois semaines afin de r\u00e9duire la vir\u00e9mie, la charge virale dans les poumons et les tissus lympho\u00efdes, ainsi que l\u2019excr\u00e9tion virale li\u00e9es au circovirus porcin de type 2 (PCV2). Une AMM a \u00e9galement \u00e9t\u00e9 recommand\u00e9e pour AviGate S. Typhimurium, vaccin destin\u00e9 \u00e0 l\u2019immunisation active des poulets sains pour r\u00e9duire l\u2019excr\u00e9tion f\u00e9cale et la colonisation des organes internes par Salmonella Typhimurium.<\/p>\n<p>Plusieurs variations d\u2019AMM ont \u00e9t\u00e9 approuv\u00e9es. Vectormune HVT-AIV voit l\u2019ajout de la dinde comme nouvelle esp\u00e8ce cible et une augmentation du titre minimal par dose. Firocoxib CP-Pharma inclut d\u00e9sormais le cheval comme nouvelle esp\u00e8ce cible. Pour Innovax ND-H5, la variation approuv\u00e9e permet de satisfaire une obligation sp\u00e9cifique en compl\u00e9tant les donn\u00e9es de stabilit\u00e9 n\u00e9cessaires pour justifier une dur\u00e9e de conservation de 36 mois du produit fini.<\/p>\n<p>Concernant les antiparasitaires, la sp\u00e9cialit\u00e9 Felpreva (tigolaner \/ \u00e9modespide \/ praziquantel) b\u00e9n\u00e9ficie d\u2019une extension d\u2019indication pour le traitement des infestations par les tiques Ixodes hexagonus et Rhipicephalus sanguineus. Vectra 3D (dinot\u00e9furane \/ pyriproxyf\u00e8ne \/ perm\u00e9thrine) se voit ajouter une indication de r\u00e9duction du risque d\u2019infection par Leishmania infantum transmise par les phl\u00e9botomes (Phlebotomus spp.) pendant un mois apr\u00e8s administration.<\/p>\n<p>Plusieurs variations visent l\u2019actualisation des informations de s\u00e9curit\u00e9 \u00e0 la suite du processus de gestion des signaux men\u00e9 par les titulaires d\u2019AMM. Pour Credelio \/ AdTab (lotilaner), la mention de \u00ab crise convulsive \u00bb comme effet ind\u00e9sirable tr\u00e8s rare est ajout\u00e9e \u00e0 l\u2019information produit. Pour Easotic (ac\u00e9pionate d\u2019hydrocortisone \/ sulfate de gentamicine \/ nitrate de miconazole), \u00ab inflammation au site d\u2019application \u00bb est ajout\u00e9e comme effet ind\u00e9sirable tr\u00e8s rare. Pour Galliprant (grapiprant), \u00ab ulc\u00e9ration gastro-intestinale \u00bb est d\u00e9sormais mentionn\u00e9e comme effet ind\u00e9sirable tr\u00e8s rare.<\/p>\n<p>Enfin, dans le cadre d\u2019une proc\u00e9dure de conseil scientifique relevant de l\u2019article 141(1)(i) du r\u00e8glement (UE) 2019\/6, le Comit\u00e9 a d\u00e9cid\u00e9 de prolonger le calendrier d\u2019examen concernant des m\u00e9dicaments v\u00e9t\u00e9rinaires contenant de l\u2019amoxicilline seule, utilis\u00e9s chez le porc dans l\u2019eau de boisson ou l\u2019alimentation pour des indications respiratoires. Cette prolongation vise \u00e0 tenir compte d\u2019\u00e9l\u00e9ments r\u00e9vis\u00e9s (non d\u00e9taill\u00e9s dans la source). Ce point pr\u00e9sente un int\u00e9r\u00eat potentiel pour le suivi des usages d\u2019antibiotiques en \u00e9levage au niveau europ\u00e9en. (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l&rsquo;IA)\u00a0\u200b<a href=\"https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-veterinary-medicinal-products-cvmp-8-10-september-2026\" target=\"_blank\" class=\"feedzy-rss-link-icon\">Lire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Le Comit\u00e9 des m\u00e9dicaments \u00e0 usage v\u00e9t\u00e9rinaire (CVMP) de l\u2019Agence europ\u00e9enne des m\u00e9dicaments a adopt\u00e9 plusieurs avis positifs portant sur des autorisations de mise sur le march\u00e9 (AMM) et des [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":17698,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[31,2],"tags":[257,227,226],"class_list":["post-17712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-politiques-europeennes-sante-social-travail","category-sante-publique-et-systeme-de-soins","tag-ema","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/17712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17712"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/17712\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/17698"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}